{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-peptic-ulcer/prescribing-information/h2-receptor-antagonists/","result":{"pageContext":{"chapter":{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists","depth":2,"htmlHeader":"<!-- begin field 6bc9dded-f33e-47df-a422-035c0896a9bf --><h2>H2-receptor antagonists</h2><!-- end field 6bc9dded-f33e-47df-a422-035c0896a9bf -->","summary":"","htmlStringContent":"<!-- begin item ae281d6f-7197-402a-a615-4e21aeac46b9 --><!-- end item ae281d6f-7197-402a-a615-4e21aeac46b9 -->","topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","lastRevised":"Last revised in October 2019","chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","fullItemName":"Management","slug":"management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"70eb7a27-c9ce-5fbf-a125-8149af32125a","slug":"choice-of-h2-receptor-antagonist","fullItemName":"Choice of H2-receptor antagonist","depth":3,"htmlHeader":"<!-- begin field 02ddf52d-1c7b-4cb9-ad80-b9b2bbf9e142 --><h3>Choice of H2-receptor antagonist</h3><!-- end field 02ddf52d-1c7b-4cb9-ad80-b9b2bbf9e142 -->","summary":"","htmlStringContent":"<!-- begin item 94f2e417-451d-4455-8a86-e0a4370caeee --><!-- begin field 1331bec6-5935-404d-ae2c-74f89c7a8727 --><ul><li>Table 2 shows the recommended doses of ranitidine, famotidine, and nizatidine histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) for the management of people with peptic ulcer disease.</li></ul><p><strong>Table 2</strong><strong>. </strong>Recommended doses of H<sub>2</sub>RAs for the management of people with peptic ulcer disease.</p><table><thead><tr><th colspan=\"1\"><p>H<sub>2</sub>RA</p></th><th colspan=\"1\"><p>Usual treatment dose</p></th></tr></thead><tbody><tr><td colspan=\"1\">Ranitidine</td><td colspan=\"1\">150 mg twice a day (or 300 mg at night)</td></tr><tr><td colspan=\"1\">Famotidine</td><td colspan=\"1\">40 mg at night (20 mg at night maintenance dose)</td></tr><tr><td colspan=\"1\">Nizatidine</td><td colspan=\"1\">150 mg twice a day or 300 mg in the evening (150 mg at night maintenance dose)</td></tr><tr><td colspan=\"2\">Note: cimetidine is also licensed for the treatment of dyspepsia symptoms, however it is not recommended as there is a higher risk of drug interactions, due to inhibition of cytochrome P450 enzymes.</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</td></tr></tbody></table><!-- end field 1331bec6-5935-404d-ae2c-74f89c7a8727 --><!-- end item 94f2e417-451d-4455-8a86-e0a4370caeee -->","subChapters":[]},{"id":"33b8142b-2c27-5f1e-8442-ccb8e0199da8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 11d76250-09da-4d47-a04b-a76d00f0ea3c --><h3>Contraindications and cautions</h3><!-- end field 11d76250-09da-4d47-a04b-a76d00f0ea3c -->","summary":"","htmlStringContent":"<!-- begin item 7b63ac86-b23d-46fa-8c44-a76d00f0e826 --><!-- begin field de09c3bf-41cf-4883-a789-a76d00f0ea3c --><ul><li><strong>Histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as H<sub>2</sub>RAs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking an H<sub>2</sub>RA and subsequently needs an endoscopy, the H<sub>2</sub>RA should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>H<sub>2</sub>RAs should be prescribed with caution in people with renal impairment:</strong><ul><li>For ranitidine, if the estimated glomerular filtration rate (eGFR) is less than 50 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal daily dose.</li><li>For famotidine, if the eGFR is less than 50 mL/minute/1.73 m<sup>2</sup>, prescribe the normal dose once every 36–48 hours, or half the normal daily dose.</li><li>For nizatidine, if the eGFR is 20–50 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal daily dose; if the eGFR is less than 20 mL/minute/1.73 m<sup>2</sup>, prescribe one-quarter of the normal daily dose.</li></ul></li><li><strong>Nizatidine should be prescribed with caution for people with hepatic impairment.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field de09c3bf-41cf-4883-a789-a76d00f0ea3c --><!-- end item 7b63ac86-b23d-46fa-8c44-a76d00f0e826 -->","subChapters":[]},{"id":"eceecbdd-17ad-51f4-aaae-f2d0c41bca84","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3f7a84a2-d0ae-4e78-b2df-a76d00f0fc1d --><h3>Adverse effects</h3><!-- end field 3f7a84a2-d0ae-4e78-b2df-a76d00f0fc1d -->","summary":"","htmlStringContent":"<!-- begin item 480e469f-b5b9-4669-8e31-a76d00f0fa24 --><!-- begin field 26e4b558-a197-4645-b8f9-a76d00f0fc1d --><ul><li>Adverse effects of histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) are uncommon and include diarrhoea, headache, dizziness, rash, and tiredness.</li><li>Rare or very rare adverse effects include hepatitis, cholestatic jaundice, bradycardia, depression, confusion, hallucinations, leucopenia, thrombocytopenia, and pancytopenia, arthralgia, and myalgia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field 26e4b558-a197-4645-b8f9-a76d00f0fc1d --><!-- end item 480e469f-b5b9-4669-8e31-a76d00f0fa24 -->","subChapters":[]},{"id":"e5ff15b3-5cfe-57fe-acb1-c381c1d82f69","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field cefc1998-5a90-40d0-b20d-a76d00f10c4b --><h3>Drug interactions</h3><!-- end field cefc1998-5a90-40d0-b20d-a76d00f10c4b -->","summary":"","htmlStringContent":"<!-- begin item 65dfc3ed-bdd9-4209-8bda-a76d00f10a5f --><!-- begin field 69eaa530-2f09-4b56-866d-a76d00f10c4b --><ul><li><strong>Possible drug interactions with histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) include:</strong><ul><li>Azole antifungals — because of decreased gastric acidity, the absorption of ketoconazole or itraconazole may be reduced if taken with an H<sub>2</sub>RA.</li><li>Protease inhibitors — atazanavir plasma levels are reduced by H<sub>2</sub>RAs. The manufacturer of atazanavir advises adjustment of the doses of both drugs when given with an H<sub>2</sub>RA. Seek specialist advice as needed.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field 69eaa530-2f09-4b56-866d-a76d00f10c4b --><!-- end item 65dfc3ed-bdd9-4209-8bda-a76d00f10a5f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}